ERBB2 and breast carcinoma: Altogether, these data suggest that TBX3 suppression or loss mimics SIRT6-OE and amplification in HER2-positive breast cancer and demands for further future specific investigations about their interaction/co-regulation and their role in therapy resistance, relapse and lung metastasis.